Medicare Part B drugs and biologicals
Medicare Part B pays for a defined set of outpatient drugs and biologicals — generally products that are not usually self-administered and are furnished incident to a practitioner's service, supplied through durable medical equipment, or covered under specific statutory categories such as certain vaccines. These items sit alongside professional services under Medicare Part B billing, but they follow their own pricing methodology, coding conventions, and coverage rules. Most separately payable Part B drugs are reimbursed under an average sales price (ASP) framework, priced quarterly by CMS, and billed with product-specific HCPCS Level II codes whose billing units must be reported precisely. Because covered drug lists, ASP files, contractor policies, and program design change over time, the specific amounts and rules described here vary by Medicare Administrative Contractor, plan, jurisdiction, and effective date, and should be confirmed against current CMS guidance.
Updated 9 min read
Reviewed by Anwaar Tayyab
Director of Billing Operations ·
On this page
Key takeaways
- Part B covers a limited, defined set of drugs and biologicals — chiefly those not usually self-administered and furnished incident to a service, through covered DME, or under specific statutory categories such as certain vaccines and immunosuppressives.
- Most separately payable Part B drugs are paid under an average sales price (ASP) methodology that CMS updates quarterly; the actual payment limits, add-on percentages, and files change by quarter and by statute.
- Accurate claims depend on the correct HCPCS Level II code, the right number of billing units for the dosage administered, and — where required — National Drug Code reporting and discarded-drug documentation.
- Coverage turns on medical necessity and on coverage determinations: a national coverage determination applies the same way in every jurisdiction, while local coverage determinations and each contractor's self-administered drug exclusion list vary by jurisdiction and by date.
- Part B drug rules interact with Medicare Advantage, Medicare Secondary Payer, prior authorization, and timely filing, so billing teams verify the payer and current policy before submitting.
What counts as a Part B drug or biological
Part B does not function as a general outpatient pharmacy benefit; that role belongs largely to Part D. Instead, Part B covers drugs and biologicals that fall into specific statutory and regulatory categories. Understanding those categories is the starting point for correct billing, and the boundaries are set by CMS rather than by any single payer or practice.
- Drugs that are not usually self-administered and are furnished incident to a physician's or other practitioner's service in an office or outpatient setting.
- Drugs administered through covered durable medical equipment, such as certain infusion or nebulizer drugs.
- Specific categories named in statute, including certain vaccines, immunosuppressive drugs after a covered transplant, some oral anti-cancer and anti-emetic drugs, and certain other defined products.
- Biologicals, including biosimilars, that meet the same incident-to and coverage conditions as other Part B drugs.
Self-administered drug exclusion
How Part B drug payment works
Payment for most separately payable Part B drugs is built on an average sales price methodology established by statute. Manufacturers report sales data to CMS, which calculates payment limits and publishes ASP pricing files on a quarterly basis. Because the files change every quarter, the specific dollar figure for any given product is date-dependent and should be drawn from the current file rather than memory.
The ASP payment limit typically includes a statutory add-on percentage applied to the reported price, and separate provisions can apply to biosimilars, new products without established ASP data, and drugs paid under other systems such as the hospital outpatient framework. These add-on percentages and special rules are set in law and regulation and have been adjusted over time, so billing teams treat the current CMS pricing file and program instructions as the authority. This drug-specific pricing sits apart from the broader Medicare fee schedules that govern professional services.
Rates and policy evolve
Coding, billing units, and discarded drugs
Part B drugs are reported with product-specific codes from the HCPCS Level II code set, maintained by CMS. Each code corresponds to a defined billing unit of measure, and the number of units billed must reflect the actual dosage administered relative to that billing unit — not the number of vials, syringes, or administrations. Mismatched units are a frequent source of a denial or a post-payment adjustment.
- HCPCS Level II drug codes
- Product-level codes used to identify the specific drug or biological billed. The descriptors and the code set are maintained by CMS; billing teams describe the concept rather than reproducing descriptor text. Most sit in the range whose codes begin with J, which is why they are commonly called J-codes — but the letter is a filing convention rather than a payment category, and a covered product may carry a temporary code or none at all. What a J-code is covers the family, and what to do when the product has no code in it.
- Billing units
- The unit of measure tied to each code. Reported units are calculated from the administered dose, and rounding conventions and unit definitions vary by product.
- National Drug Code (NDC)
- For many drugs, the NDC identifying the specific product and package may be required on the claim in addition to the HCPCS code; requirements differ by contractor and program. Where it is required, the quantity reported against it is counted in the NDC label's own unit of measure rather than the code's, so one line can carry two different and equally correct numbers — NDC units on drug claims covers how each is derived.
- Not-otherwise-classified (NOC) codes
- When no specific code exists, an unclassified code may be used with supporting narrative detail such as drug name, dose, and NDC so the contractor can price the claim manually.
When a single-dose container yields more drug than is administered, Medicare has established conventions for reporting the amount actually given and the amount discarded, using designated HCPCS modifiers and supporting documentation. The specifics of which modifier applies, and to which products, are governed by CMS policy and change over time, so current instructions should be consulted before appending any modifier.
Coverage determinations and documentation
Whether a Part B drug is covered in a given clinical situation is governed by national coverage determinations and, where none applies, by local coverage determinations issued by the servicing contractor. Both kinds of policy define covered indications, frequency limits, and required diagnoses, but they do not have the same reach: a national coverage determination settles the question the same way everywhere, while a local coverage determination binds only the contractor that issued it, so the same drug can be treated differently from one jurisdiction to another. The broader framework is described in national and local coverage determinations.
- Documentation should establish medical necessity for the drug, including the diagnosis, dose, route, and administration details.
- Where a service may not be covered, an Advance Beneficiary Notice may be appropriate so the beneficiary understands potential financial responsibility.
- Some drugs are subject to prior authorization or step-therapy requirements that vary by program and contractor.
Confirm the current policy
Billing workflow and program variation
Many Part B drugs are furnished under a buy-and-bill model, in which the practice acquires the drug, administers it, and bills Medicare. That is not merely a common arrangement: a practice that did not purchase the drug cannot bill for it, and because Part B drug payment is available only on an assignment-related basis, it cannot recover a shortfall from the patient either. This makes accurate acquisition tracking, unit reporting, and coverage verification central to the revenue cycle. Several billing dimensions vary by program and payer:
| Dimension | What varies | Where it is defined |
|---|---|---|
| Payment amount | ASP-based limits and add-on provisions change quarterly and by statute | Current CMS ASP pricing files and program instructions |
| Coverage | Indications, frequency, and SAD status differ by jurisdiction where no national determination applies | Local coverage determinations and contractor SAD lists |
| Payer of record | Traditional Medicare versus a Medicare Advantage plan | Beneficiary eligibility and plan enrollment |
| Order of payment | Whether Medicare pays primary or secondary | Medicare Secondary Payer rules |
Every row reflects a rule that varies; none should be treated as a fixed figure.
When a patient is enrolled in a Medicare Advantage plan, the plan — not the MAC — sets coverage, pricing, and authorization rules for Part B drugs, and claims go to the plan. Where another payer is primary, Medicare Secondary Payer rules determine the order of billing. Claims also remain subject to Medicare timely filing limits, and unit or coverage errors surface among common Medicare billing denials.
Frequently asked questions
Does Medicare Part B cover prescription drugs the patient takes at home?
Generally no. Part B is not a broad outpatient pharmacy benefit; that role belongs largely to Part D. Part B covers drugs and biologicals that fall into defined categories, chiefly those not usually self-administered and furnished incident to a service, through covered durable medical equipment, or under specific statutory categories such as certain vaccines and immunosuppressives. Drugs a patient would typically administer to themselves are generally excluded, and each contractor maintains its own self-administered drug list.
How are Part B drugs paid?
Most separately payable Part B drugs are paid under an average sales price methodology set by statute. CMS calculates payment limits from manufacturer-reported data and publishes pricing files quarterly. Add-on percentages and special provisions for biosimilars or new products are defined in law and regulation and change over time, so the current CMS file is the authority for any specific amount.
Why do billing units matter so much for drug claims?
Each HCPCS Level II drug code is tied to a defined billing unit of measure. The number of units reported must reflect the dose actually administered relative to that unit, not the number of vials or administrations. Mismatched units are a common cause of denials and post-payment adjustments, which is why dose-to-unit calculation and, where required, NDC reporting are core steps.
What is discarded-drug reporting?
When a single-dose container holds more drug than is administered, Medicare has conventions for reporting both the amount given and the amount discarded, using designated HCPCS modifiers and supporting documentation. Which modifier applies, and to which products, is governed by CMS policy and changes over time, so current instructions should be checked before appending a modifier.
Do Part B drug rules apply the same way under Medicare Advantage?
No. For a beneficiary enrolled in a Medicare Advantage plan, the plan sets coverage, pricing, and authorization rules for Part B drugs and receives the claim, rather than the Medicare Administrative Contractor. Teams confirm the payer of record and the plan's current policy before billing.
Related glossary terms
Key terms that appear throughout Part B drug and biological billing.
Related reading
Continue with related topics in the Medicare billing cluster.
Medicare Part B billing
How professional services are billed under Part B, the setting in which most Part B drugs are administered.
Medicare fee schedules explained
How Medicare sets payment amounts, and how drug pricing differs from professional-service fee schedules.
National and local coverage determinations
How NCDs and LCDs define covered indications and frequency for drugs and other services.
Common Medicare billing denials
Frequent denial reasons, including the unit and coverage errors that affect drug claims.
Prior authorization for medications
How drug-level prior authorization and step-therapy requirements are handled.
Oncology billing
The specialty where the discarded-drug convention bites hardest — a separately payable single-dose-container line has to attest either what was thrown away or that nothing was.
Rheumatology billing
Where the self-administered exclusion decides the therapy itself — how contractors apply the more-than-half test, per indication and by route, to the subcutaneous biologics the specialty runs on.
Authoritative sources
- 42 U.S.C. § 1395w-3a — Use of average sales price payment methodology (Social Security Act § 1847A) (opens in a new tab)
United States Code, 2023 Edition (GPO). The statute the whole payment framework rests on. Subsection (b)(1) sets the payment amount for a billing and payment code at 106 percent of the volume-weighted average sales price for a multiple source drug, 106 percent of the amount determined for a single source drug or biological — or, where the product is a selected drug for a price applicability period, 106 percent of the maximum fair price — and a separate calculation for biosimilar biological products. Subsection (b)(4) makes the single source amount the lesser of average sales price and wholesale acquisition cost. Subsection (b)(6)(B) defines the billing unit as the identifiable quantity associated with a billing and payment code. Subsection (f) is the quarterly average sales price reporting obligation on manufacturers. Subsection (i) carries the inflation rebate for single source drugs whose prices rise faster than inflation, and paragraph (5) provides that for a part B rebatable drug furnished on or after April 1, 2023 whose payment amount exceeds the inflation-adjusted payment, beneficiary coinsurance is computed as 20 percent of the inflation-adjusted amount rather than of the payment amount.
- 42 CFR 414.904 — Average sales price as the basis for payment (opens in a new tab)
eCFR. The regulation that operates the average sales price method. Paragraph (a) pays the lesser of the actual charge on the claim or 106 percent of the average sales price, calculates the payment limit from the amount of product on the FDA-approved label, and makes no payment for product in excess of that labeled amount. Paragraph (d)(1) caps a single source drug at the lesser of 106 percent of average sales price or 106 percent of wholesale acquisition cost. Paragraph (f) states that the payment limits are updated quarterly, with an exception for infusion drugs. Paragraph (j) sets the biosimilar amount as the biosimilar's own average sales price plus 6 percent of the reference product amount, or 8 percent for a qualifying biosimilar during its applicable period.
- CMS Medicare Benefit Policy Manual, Pub. 100-02, Chapter 15, §§ 50 and 50.2 — Drugs and biologicals (opens in a new tab)
Centers for Medicare & Medicaid Services. Section 50 sets the conditions a drug must meet to be covered — that it is of a type not usually self-administered, meets the incident-to requirements, is reasonable and necessary, and has not been found less than effective — and notes the statutory exceptions that cover some self-administered products, naming blood-clotting factors, immunosuppressive therapy, erythropoietin for dialysis patients, osteoporosis drugs for certain homebound patients, and certain oral cancer drugs. Section 50.2 is the self-administered exclusion itself: each contractor must make its own determination on each drug, 'usually' means more than 50 percent of the time across all Medicare beneficiaries who use the drug, the determination is made separately for each indication and then weighted, and route carries presumptions — intravenous and intramuscular delivery presumed not usually self-administered, subcutaneous injection presumed self-administered absent evidence to the contrary. Paragraph G requires every A/B MAC and DME MAC to publish, on its own website, the list of injectable drugs subject to the exclusion together with the data and rationale behind it.
- CMS Medicare Claims Processing Manual, Pub. 100-04, Chapter 17 — Drugs and biologicals (opens in a new tab)
Centers for Medicare & Medicaid Services. The operational chapter. Section 70 requires the drug to be identified by HCPCS code on claims to A/B MACs and by National Drug Code on claims to DME MACs, and requires units to be entered in multiples of the units shown in the HCPCS narrative description — or, where the NDC is required, in multiples of the units shown in the NDC label description — repeating the code across lines where the units exceed the field. Section 40 carries the discarded-drug convention: payment is available for the discarded remainder of a single-dose container or single-use package as well as the dose administered, up to the labeled amount; the administered amount goes on one line with no modifier and the discarded amount on a second line with the JW modifier; since July 1, 2023 the JZ modifier attests that nothing was discarded; and the discarded amounts must be recorded in the patient's medical record. Section 10.1 sets the payment rules for drugs subject to the inflation-adjusted coinsurance policy, and section 20 covers the payment allowance limit and the not-otherwise-classified pricing file.
- 42 U.S.C. § 1395ff(f) — Review of coverage determinations, including the statutory definitions of national and local coverage determinations (Social Security Act § 1869(f)) (opens in a new tab)
United States Code, 2023 Edition (GPO). Subsection (f) governs review of coverage determinations, and it is where the statute defines the two kinds of coverage policy. Paragraph (f)(1)(B) defines a national coverage determination as a determination by the Secretary whether a particular item or service is covered nationally, excluding code assignment and payment amount. Paragraph (f)(2)(B) defines a local coverage determination as a determination by a fiscal intermediary or a carrier whether a particular item or service is covered on an intermediary- or carrier-wide basis, in accordance with section 1395y(a)(1)(A) (Social Security Act § 1862(a)(1)(A)) — which is why a local determination can differ from one jurisdiction to the next and a national determination cannot.